TY - JOUR
T1 - Recurrent bacterial meningitis by three different pathogens in an isolated asplenic child
AU - Uchida, Yoshiko
AU - Matsubara, Kousaku
AU - Wada, Tamaki
AU - Oishi, Kazunori
AU - Morio, Tomohiro
AU - Takada, Hidetoshi
AU - Iwata, Aya
AU - Yura, Kazuo
AU - Kamimura, Katsunori
AU - Nigami, Hiroyuki
AU - Fukaya, Takashi
PY - 2012/8
Y1 - 2012/8
N2 - Isolated congenital asplenia (ICA) is a rare condition at risk for overwhelming infection. When complicated by invasiveinfection, the mortality remains high, at greater than 60%. We describe a girl with ICA who developed recurrent meningitis bythree different pathogens. The first, meningitis by Escherichia coli, occurred 4 days after premature birth. The other twopathogens were serotype 6B Streptococcus pneumoniae and Haemophilus influenzae type b (Hib), at 18 and 25 months of age,respectively. The patient was successfully treated with prompt antimicrobial therapy in all episodes. Serumanti- polyribosylribitol phosphate (PRP) and anti-6B-type pneumococcal antibodies were below the levels for protectiveactivity after natural infections. Although anti-PRP antibody was significantly increased after Hib vaccination, two (6B and19F) of seven serotype-specific pneumococcal antibodies were not elevated to protective levels after the second 7-valentpneumococcal conjugate vaccine (PCV7). We, therefore, added a third PCV7. To our knowledge, this is the first neonatal ICApatient with invasive infection and the first case of bacterial meningitis occurring three times. Our findings indicate thatmonitoring of immune responses after natural infections and vaccinations, and reevaluations of vaccine schedule, areimportant for ICA patients to prevent subsequent invasive infections.
AB - Isolated congenital asplenia (ICA) is a rare condition at risk for overwhelming infection. When complicated by invasiveinfection, the mortality remains high, at greater than 60%. We describe a girl with ICA who developed recurrent meningitis bythree different pathogens. The first, meningitis by Escherichia coli, occurred 4 days after premature birth. The other twopathogens were serotype 6B Streptococcus pneumoniae and Haemophilus influenzae type b (Hib), at 18 and 25 months of age,respectively. The patient was successfully treated with prompt antimicrobial therapy in all episodes. Serumanti- polyribosylribitol phosphate (PRP) and anti-6B-type pneumococcal antibodies were below the levels for protectiveactivity after natural infections. Although anti-PRP antibody was significantly increased after Hib vaccination, two (6B and19F) of seven serotype-specific pneumococcal antibodies were not elevated to protective levels after the second 7-valentpneumococcal conjugate vaccine (PCV7). We, therefore, added a third PCV7. To our knowledge, this is the first neonatal ICApatient with invasive infection and the first case of bacterial meningitis occurring three times. Our findings indicate thatmonitoring of immune responses after natural infections and vaccinations, and reevaluations of vaccine schedule, areimportant for ICA patients to prevent subsequent invasive infections.
UR - http://www.scopus.com/inward/record.url?scp=84865120958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865120958&partnerID=8YFLogxK
U2 - 10.1007/s10156-011-0341-z
DO - 10.1007/s10156-011-0341-z
M3 - Article
C2 - 22147274
AN - SCOPUS:84865120958
SN - 1341-321X
VL - 18
SP - 576
EP - 580
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 4
ER -